AzTrials
AzTrials

Keratinized MucosaXCM versus FGGNCT07056959

Efficacy of Collagen Matrix for Peri-implant Soft Tissue Phenotype Modification

A study testing Soft tissue substitute for peri-implant phenotype modification in people with Keratinized Mucosa and Keratinized Tissue, run by Mohammed Bin Rashid University of Medicine and Health Sciences at 1 site in United Arab Emirates.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

A stable band of keratinized mucosa (KM) around dental implants is thought to minimize tissue recession and provide resistance against mechanical, chemical, and microbial challenges, thereby preserving peri-implant tissue health. Read more about this study

Who is it for?
Ages 21 years and older
Conditions the study is for
Keratinized Mucosa, Keratinized Tissue
What is being tested?
Soft tissue substitute for peri-implant phenotype modification
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
1 siteUnited Arab Emirates
Study dates
1 Nov 2025to Jun 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Aged 21 or over.
  • Insufficient KM width (< 2 mm) at the buccal aspect of implants at time of healing abutment placement, either for single anterior or posterior implants.
  • Controlled oral hygiene (full-mouth plaque and bleeding scores ≤ 25% at baseline).
  • Good compliance and commitment to attend follow-up review appointments.
  • Willing to provide informed consent.

Who cannot join

  • Smoking
  • Untreated localized or generalized periodontal diseases
  • Uncontrolled systemic diseases
  • Long term use of non-steroidal anti-inflammatory medications
  • History of malignancy, radiotherapy or chemotherapy
  • Collagen allergy
  • History of mucogingival surgery

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Maanas shah, BDS MSD CAGS MRACDS contact

971556102178

maanas.shah@dubaihealth.ae

United Arab Emirates1 site, 1 recruiting
  • Dubai Dental Hospital

    Dubai

    Maanas Shah, 0097143838951, maanas.shah@dubaihealth.ae

    Recruiting

Other trials in United Arab Emirates

About this study

Official title: Efficacy of Collagen Matrix for Peri-implant Soft Tissue Phenotype Modification: A Randomized Controlled Trial

A stable band of keratinized mucosa (KM) around dental implants is thought to minimize tissue recession and provide resistance against mechanical, chemical, and microbial challenges, thereby preserving peri-implant tissue health. Soft tissue augmentation is often employed to enhance the soft tissue phenotype in such cases. While autogenous grafts such as free gingival grafts (FGG) remain the gold standard, xenogeneic collagen matrices (XCM) have emerged as promising alternatives, offering reduced patient morbidity and surgical time. This randomized controlled clinical trial aims to compare the clinical efficacy and patient-reported outcome measures (PROMs) of XCM versus FGG for soft tissue phenotype modification when performed during healing abutment connection around dental implants, with evaluations at both short-term (6 months) and long-term (1 and 2 years) intervals.

Thirty participants will be recruited at Dubai Health Dental Hospital and randomly assigned to receive either XCM (test) or FGG (control) augmentation. Clinical assessments will be conducted at baseline (T0), 2 weeks (T2w), and at 1 (T1), 3 (T3), 6 (T6), 12 (T12), and 24 (T24) months post-surgery.

Read more

The primary outcome is the change in KM width, measured from the mucosal margin to the mucogingival junction. Secondary outcomes include KM thickness, supracrestal tissue height, and soft tissue dimensional changes, assessed using intraoral scans (Trios 5) and superimposed STL files. Additional measurements include peri-implant soft tissue level and phenotype.

PROMs will be recorded in the first postoperative week and at the 3-year mark using a visual analog scale (VAS). Clinical indices such as plaque index, bleeding index, and probing depth will be evaluated at 6 months, 1 year, and 2 years. Marginal bone level changes and implant survival rates will also be tracked throughout the study period.

Read the detailed description

A stable band of keratinized mucosa (KM) around dental implants is believed to aid in minimizing tissue recession and provide resistance to mechanical, chemical, and biological challenges, thereby supporting the health of the surrounding hard and soft tissues. The evidence regarding the effect of KM on peri-implant health in animals is conflicting. Warrer et al. concluded that the presence of KM significantly reduced mucosal recession (MR) and attachment loss (AL), while Strub et al. observed no differences in recession or bone loss of peri-implant tissues between implants with and without adequate KM. Human studies evaluating the effect of KM on various peri-implant health-related parameters, have concluded that a lack of adequate KM around dental implants is associated with more plaque accumulation, tissue inflammation, MR, and AL. Moreover, since A stable band of keratinized mucosa (KM) around dental implants is believed to aid in minimizing tissue recession and provide resistance to mechanical, chemical, and biological challenges, thereby supporting the health of the surrounding hard and soft tissues. The evidence regarding the effect of KM on peri-implant health in animals is conflicting. Warrer et al. concluded that the presence of KM significantly reduced mucosal recession (MR) and attachment loss (AL), while Strub et al. (1991) observed no differences in recession or bone loss of peri-implant tissues between implants with and without adequate KM . Human studies evaluating the effect of KM on various peri-implant health-related parameters, have concluded that a lack of adequate KM around dental implants is associated with more plaque accumulation, tissue inflammation, MR, and AL. Moreover, since most patients do not consistently adhere to supportive peri-implant maintenance programs, it is important to evaluate the role of peri-implant soft tissue characteristics in the development of peri-implant diseases. A cross-sectional study examining the significance of KM on peri-implant and adjacent natural teeth was conducted on erratic peri-implant maintenance compliers. Implant sites with KM band width of <2mm have been associated with significantly poorer clinical and radiographic parameters, suggesting a higher risk for peri-implant diseases. In response to this, a consensus report from the DGI/SEPA/Osteology Workshop emphasized the importance of measuring KM width as a part of the routine oral examination of peri-implant hard and soft tissues. In addition, if the prosthesis obstructs the identification of the peri-implant mucosal margin, its removal may be considered. Moreover, Implants with insufficient KM width require enhanced maintenance care, as they are more susceptible to plaque buildup and the development of peri-implant mucosal inflammation.

Soft tissue augmentation procedures are often implemented to improve the peri-implant soft tissue phenotype, namely the KM width, KM thickness, and supracrestal tissue height. Similar to natural teeth, soft tissue augmentation methods around implants have included autogenous techniques such as bilaminar- or apically positioned flap (APF) either alone or in combination with free gingival grafts (FGG), and connective tissue grafts (CTG). These approaches have demonstrated favourable medium to long term outcomes. Although autogenous grafts are still considered the gold standard for soft tissue augmentation procedures, a secondary interventional site for graft harvesting increases patients' morbidity. Additional intra and postoperative complications such as palatal bleeding, edema, infection, and sometimes necrosis has also been identified. Moreover, postoperative pain perception following palatal graft harvesting worsened and required additional treatment of the wound site to minimize discomfort and the need for analgesics. Additionally, the effectiveness of soft tissue augmentation may be limited by the availability of connective tissue at the donor site, particularly in cases requiring augmentation for deep horizontal alveolar defects or extensive edentulous gaps. To overcome these shortcomings, acellular dermal matrix (ADM) or xenogeneic collagen matrix (XCM) have been developed that may be associated with reduced pain perception, reduced surgery time, as they do not require an additional surgical site. While short term primary outcomes of achieving adequate zone of KM using these soft tissue substitutes have been comparable to those achieved with autogenous grafts, the efficacy of soft tissue augmentation procedures aimed at modifying the peri-implant soft tissue phenotype and their impact on peri-implant health have remained inconclusive . The network meta-analysis of randomized controlled trials demonstrated that bilaminar approaches involving CTG or ADM obtained the highest amount of KM gain, whereas APF in combination with FGG was the most effective technique for increasing KM width. KM augmentation via APF alone was associated with a significant reduction in peri-implant parameters like probing depths and plaque index, regardless of the soft tissue grafting material used, whereas bilaminar techniques with CTG or XCM showed beneficial effects on marginal bone level stability. The non-inferiority of XCM as compared to CTG or ADM have also been evaluated in various multi-center randomized controlled trials. Soft tissue augmentation with a cross-linked porcine-derived XCM at the time of implant placement showed substantial shrinkage of about 75% in areas between augmentation and 1-year follow-up. Overall, while 25% of the original soft tissue defect was eliminated by augmentation, XCM was deemed safe with no postoperative complications and limited marginal bone loss . Also, there is no consensus comparing the effectiveness of autogenous grafts and soft-tissue substitutes in achieving a stable, non-mobile peri-implant mucosa, which should be a key objective of these surgical procedures . Furthermore, there is no evidence regarding patient's preferences, studies assessing aesthetic outcomes have shown that soft tissue substitutes tend to deliver better results than FGG. However, no significant differences were observed when compared to CTG.

The timing of soft tissue augmentation around implants is a crucial factor, that may influence the choice of graft material, based on type of defect, quality and quantity of residual soft tissue and clinician's preference. The procedure is commonly performed before or at the time of implant placement, at the time of healing abutment connection or after final restorative phase. Soft tissue augmentation prior to implant placement or at healing abutment connection are considered the gold standard time points, due to the possibility of achieving complete coverage of the graft material through adequate tissue handling. Conversely, augmentation procedures at the time of implant placement or after crown delivery appears to be less predictable due to the different healing approaches and the unexpected shrinkage that may occur.

While the effectiveness of the XCM (Mucograft©, Geistlich Pharma® AG, Wolhusen, Switzerland) as a substitute for FGG around implants has been confirmed, its impact on peri-implant soft tissue phenotype modification when placed at the time of healing abutment connection requires further validation.

The aim of this randomized clinical trial is to evaluate clinical efficacy and patient-reported outcome measures (PROMs) of XCM compared to FGG for phenotype modification when conducted at time of healing abutment connection around dental implants over a short -term (6 months) and a long term (1- and 2- years) follow-up.

Being tested
Soft tissue substitute for peri-implant phenotype modification, Control Group - Free gingival graft for soft tissue augmentation
Keywords
keratinized mucosa, implants, soft tissue augmentation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Soft tissue substitute for peri-implant phenotype modificationProcedure or surgery

    XCM (Mucograft©, Geistlich Pharma® AG, Wolhusen, Switzerland) placed at the time of healing abutment connection and its impact on peri-implant soft tissue phenotype modification when

  • Control Group - Free gingival graft for soft tissue augmentationProcedure or surgery

    Free gingival graft around implants placed at the time of healing abutment connection and its impact on peri-implant soft tissue phenotype modification

Study groups in NCT07056959
Study groupRoleWhat they receive
Test group - MucograftExperimentalXCM (Mucograft©, Geistlich Pharma® AG, Wolhusen, Switzerland) when placed at the time of healing abutment connection and its impact on peri-implant soft tissue phenotype modification
Receives: Procedure: Soft tissue substitute for peri-implant phenotype modification
Control Group - Free gingival graftActive comparatorUse of Free gingival graft placed at the time of healing abutment connection and its impact on peri-implant soft tissue phenotype modification
Receives: Procedure: Control Group - Free gingival graft for soft tissue augmentation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Changes in Keratinized Mucosa width

    Changes in KM width - as measured from the free mucosal margin to the mucogingival junction at the mid-buccal aspect of the implant abutment or crown with a UNC-15 probe; at the follow-up time point relative to the baseline at T0

    Measured: 6 months

Secondary outcomes (1)
  1. Changes in KM thickness and supracrestal tissue height

    calculating percentage of KM width (shrinkage), KM thickness and supracrestal tissue attachment reduction at the follow-up time point relative to the baseline at T0.

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Jul 2025
  2. Study start1 Nov 2025
  3. Primary completionDec 2027 (estimated)
  4. Study completionJun 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07056959
Sponsor's protocol ID
MBRU-HBMCDM-RG2025-02
Other IDs
MBRU-HBMCDM-RG2025-02
Acronym
XCM versus FGG
Status last verified
Jun 2025
First submitted
29 Jun 2025
Last updated
4 Dec 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: Individual participant data (IPD) will be made available upon reasonable request at the time of publication, in accordance with ICMJE guidelines

Publications

  • Sanz M, Lorenzo R, Aranda JJ, Martin C, Orsini M. Clinical evaluation of a new collagen matrix (Mucograft prototype) to enhance the width of keratinized tissue in patients with fixed prosthetic restorations: a randomized prospective clinical trial. J Clin Periodontol. 2009 Oct;36(10):868-76. doi: 10.1111/j.1600-051X.2009.01460.x. Epub 2009 Aug 12.

    PubMed 19678861
  • Naenni N, Bienz SP, Benic GI, Jung RE, Hammerle CHF, Thoma DS. Volumetric and linear changes at dental implants following grafting with volume-stable three-dimensional collagen matrices or autogenous connective tissue grafts: 6-month data. Clin Oral Investig. 2018 Apr;22(3):1185-1195. doi: 10.1007/s00784-017-2210-3. Epub 2017 Sep 18.

    PubMed 28924826
  • Cosyn J, Eeckhout C, De Bruyckere T, Eghbali A, Vervaeke S, Younes F, Christiaens V. A multi-centre randomized controlled trial comparing connective tissue graft with collagen matrix to increase soft tissue thickness at the buccal aspect of single implants: 1-year results. J Clin Periodontol. 2022 Sep;49(9):911-921. doi: 10.1111/jcpe.13691. Epub 2022 Jul 20.

    PubMed 35781692

Questions about this trial

What is this clinical trial studying?

A study testing Soft tissue substitute for peri-implant phenotype modification in people with Keratinized Mucosa and Keratinized Tissue, run by Mohammed Bin Rashid University of Medicine and Health Sciences at 1 site in United Arab Emirates.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 4 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Arab Emirates. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Maanas shah, BDS MSD CAGS MRACDS (971556102178, maanas.shah@dubaihealth.ae), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Changes in Keratinized Mucosa width (time frame: 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07056959, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Dec 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in